查詢結果分析
來源資料
相關文獻
- 以免疫吸附血漿析離療法治療重症肌無力症之評估
- 重症肌無力症之免疫吸附血漿析離療法:免疫吸附管之吸附性能研究
- 重症肌無力症之血漿析離療法
- 血漿析離療法引起之凝血異常:一例報告
- 雙重過濾血漿析離療法之血液學變化--每日及隔日療法之比較
- Experience in the Treatment of Myasthenia Gravis with Double Filtration Plasmapheresis
- 手術後嚴重黃疸之選擇性膽紅素吸附血漿灌流療法:一例報告
- 多發性硬化症之血液析離療法
- 雙重過濾血漿析離術過濾效能之比較--Kuraray KM8800及Asahi Plasauto iQ
- 由2004年臺灣北部--醫學中心血漿交換經驗談血漿析離之發展趨勢
頁籤選單縮合
題 名 | 重症肌無力症之免疫吸附血漿析離療法:免疫吸附管之吸附性能研究=Immunoadsorption Therapy for Myasthenia Gravis: Study on the Adsorption Capacity of an Immunoadsorption Colunmn |
---|---|
作 者 | 葉建宏; 邱浩彰; | 書刊名 | 微免與感染雜誌 |
卷 期 | 32:2 1999.06[民88.06] |
頁 次 | 頁121-125 |
分類號 | 415.695 |
關鍵詞 | 血漿析離術; 雙重過濾血漿析離術; 免疫吸附血漿析離術; 血漿交換; 重症肌無力; Plasmapheresis; Double filtration plasmapheresis; Immunoadsorption plasmapheresis; Plasma exchange; Myasthenia gravis; |
語 文 | 中文(Chinese) |
中文摘要 | 廣泛型重症肌無力患者血漿內大部分皆有濃度高低不一之乙醯膽鹼受體抗體( acetylcholine receptor antibody, AchRAb )。血漿析離療法可以使抗體急速下降,並使 病情迅速恢復。五例重度肌無力病患( 3 男 2 女,平均年齡 49.6 歲)在接受胸腺切除術 及免疫抑制療法仍控制不良前提下,接受免疫吸附血漿析離療法。 Plasmaflo AP 05W 為血 漿分離管,Immusorba TR-350 做為血漿灌流時之免疫吸附管。每個療程採隔日連續 5 次之 治療。在每次治療前後皆抽血檢驗血中 AchRAb 濃度。另外,在通過此吸附管之前與後血漿 迴路管內,每灌流 0.5L 血漿時,各抽一套血漿,檢驗其中 AchRAb 濃度。通過吸附管前之 迴路管中 AchRAb 濃度隨著灌流血漿量增加而下降,但灌流至 2L 後,部分出現回升現象。 街就吸附管對 AchRAb 清除率而言,灌流血漿量在 1L 以內可達近 100%。 當超過 2L 時, 近半數的 AchRAb 將無法被吸附管所吸附而流出。 在逐次免疫吸附血漿析離治療下, 平均 AchRAb 濃度可下降至治療前之 74.6%,52.6%,43.3%,35.8% 及 36.5%。總結,連續 4 次 ,每次 2L 的灌流血漿量應是理想的免疫吸附析離療法。 |
英文摘要 | Circulating antibodies to the acetylcholine receptor (AchRAb) are detectable in most of the patients with generalized myasthenia gravis (MG). Plasmapheresis has been shown to induce a rapid recovery in company with the decline of the AchRAb titers. Immunoadsorption plasmapheresis (IP) was performed in five patients (three men and two women, mean age 49.6 years) with advanced MG who were refractory to thymectomy and immunosuppressants. Plasmaflo AP 05W was used as a plasma separator and Immusorba TR-350 was used as an immunoadsorption cloumn for plasma perfusion. Each course of treatment consisted of 5 sessions of plasmapheresis on alternate days. Plasma was sampled before and after passage through the adsorption column. We analyzed AchRAb titer in the samples of zero time and sequentially at every 0.5 L of plasma treated. The mean titer of AchRAb in the plasma before passing the adsorption column decreased gradually after every 0.5L perfused plasma up to 2L. After perfusion of 2L plasma, the titer of AchRAb rebounded partly. The mean reduction rate of AchRAb at initial 1L perfusion of plasma was approximately 100% among sessions of treatment. When the perfusion volume was over 2L, nearly 50% of AchRAb had not adsorbed through the adsorption column among sessions. The mean titer of AchRAb fell to 74.6%, 52.6%, 43.3%, 35.8%, and 36.5% of the original level after each session of IP. In conclusion, a total of 4 sessions of IP with perfusion of 2L plasma is an ideal treatment of patients with MG in terms of functional capacity of an immunoadsorption column. |
本系統中英文摘要資訊取自各篇刊載內容。